 Jeffrey Schowinsky
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 7 | 2023 | 536 | 0.790 |
Why?
| | Brain Neoplasms | 3 | 2018 | 984 | 0.660 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 62 | 0.650 |
Why?
| | Azacitidine | 4 | 2023 | 129 | 0.590 |
Why?
| | Lipomatosis | 1 | 2015 | 3 | 0.500 |
Why?
| | HMGA2 Protein | 1 | 2015 | 8 | 0.500 |
Why?
| | Adamantinoma | 1 | 2015 | 5 | 0.490 |
Why?
| | Synovial Membrane | 1 | 2015 | 75 | 0.480 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 664 | 0.470 |
Why?
| | Eosinophilia | 1 | 2015 | 186 | 0.440 |
Why?
| | Tibia | 1 | 2015 | 166 | 0.430 |
Why?
| | Skin Neoplasms | 2 | 2018 | 761 | 0.400 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2012 | 15 | 0.400 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2012 | 69 | 0.370 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 5 | 2023 | 172 | 0.330 |
Why?
| | Soft Tissue Neoplasms | 2 | 2023 | 90 | 0.320 |
Why?
| | Clonal Evolution | 2 | 2017 | 27 | 0.260 |
Why?
| | Biopsy, Needle | 1 | 2006 | 181 | 0.260 |
Why?
| | Diagnostic Errors | 1 | 2006 | 148 | 0.250 |
Why?
| | Rectum | 1 | 2006 | 153 | 0.250 |
Why?
| | Sulfonamides | 4 | 2021 | 445 | 0.240 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1361 | 0.210 |
Why?
| | Carrier Proteins | 2 | 2017 | 696 | 0.200 |
Why?
| | Nuclear Proteins | 2 | 2017 | 592 | 0.200 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.180 |
Why?
| | Mastocytosis | 1 | 2021 | 12 | 0.180 |
Why?
| | Keratins | 2 | 2015 | 176 | 0.180 |
Why?
| | Adenocarcinoma | 1 | 2006 | 801 | 0.170 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 925 | 0.160 |
Why?
| | Fatal Outcome | 2 | 2018 | 284 | 0.160 |
Why?
| | Pyrazoles | 2 | 2021 | 364 | 0.150 |
Why?
| | Fibromatosis, Aggressive | 1 | 2017 | 18 | 0.150 |
Why?
| | Tetrahydronaphthalenes | 1 | 2017 | 31 | 0.140 |
Why?
| | Humans | 25 | 2023 | 114757 | 0.140 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1053 | 0.140 |
Why?
| | Valine | 1 | 2017 | 72 | 0.140 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.140 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 5 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 32 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 4 | 2016 | 3039 | 0.140 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2017 | 73 | 0.140 |
Why?
| | Mutation | 3 | 2017 | 3350 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2018 | 344 | 0.140 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 6 | 0.140 |
Why?
| | Lymphoma | 1 | 2017 | 177 | 0.130 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 24 | 0.130 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.130 |
Why?
| | Leukocytosis | 1 | 2015 | 35 | 0.130 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 642 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 195 | 0.130 |
Why?
| | Neoplasm, Residual | 3 | 2023 | 104 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 258 | 0.120 |
Why?
| | Lipoma | 1 | 2015 | 15 | 0.120 |
Why?
| | Tenosynovitis | 1 | 2015 | 12 | 0.120 |
Why?
| | Natalizumab | 2 | 2012 | 46 | 0.120 |
Why?
| | Middle Aged | 7 | 2021 | 26757 | 0.110 |
Why?
| | Genomic Instability | 1 | 2013 | 38 | 0.110 |
Why?
| | Tissue Culture Techniques | 1 | 2013 | 66 | 0.110 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 429 | 0.100 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 18 | 0.100 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 38 | 0.100 |
Why?
| | CD3 Complex | 1 | 2012 | 92 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 312 | 0.100 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 106 | 0.100 |
Why?
| | Female | 12 | 2023 | 59507 | 0.090 |
Why?
| | Male | 11 | 2023 | 55579 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 863 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1270 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1635 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2012 | 220 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2099 | 0.090 |
Why?
| | Neutrophils | 1 | 2015 | 1163 | 0.090 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 333 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 1895 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1022 | 0.080 |
Why?
| | Bone Marrow | 3 | 2017 | 244 | 0.080 |
Why?
| | Lymphatic Diseases | 1 | 2008 | 17 | 0.080 |
Why?
| | Neutropenia | 1 | 2008 | 125 | 0.070 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2007 | 52 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2269 | 0.070 |
Why?
| | Adult | 7 | 2023 | 30548 | 0.070 |
Why?
| | Chromosome Aberrations | 2 | 2018 | 138 | 0.070 |
Why?
| | Prognosis | 3 | 2019 | 3334 | 0.070 |
Why?
| | Racemases and Epimerases | 1 | 2006 | 11 | 0.070 |
Why?
| | Mucins | 1 | 2006 | 61 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2007 | 1340 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2006 | 153 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 173 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2021 | 6350 | 0.060 |
Why?
| | Aged | 5 | 2021 | 19094 | 0.060 |
Why?
| | Disease Progression | 2 | 2023 | 2387 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2007 | 507 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 333 | 0.060 |
Why?
| | Biopsy | 2 | 2018 | 1040 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2023 | 12515 | 0.050 |
Why?
| | Cytodiagnosis | 1 | 2023 | 29 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2023 | 64 | 0.050 |
Why?
| | World Health Organization | 1 | 2023 | 103 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 56 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2006 | 530 | 0.050 |
Why?
| | Triazines | 1 | 2021 | 36 | 0.050 |
Why?
| | Flow Cytometry | 2 | 2018 | 1086 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2019 | 9089 | 0.040 |
Why?
| | Neoplastic Stem Cells | 1 | 2023 | 334 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4420 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 183 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 233 | 0.040 |
Why?
| | Karyotyping | 1 | 2018 | 103 | 0.040 |
Why?
| | Histocytochemistry | 1 | 2018 | 79 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 379 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 10 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 13 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 7 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 17 | 0.030 |
Why?
| | Sphenoid Bone | 1 | 2016 | 15 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2017 | 292 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 151 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 44 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 259 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 182 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 731 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 372 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 313 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 936 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 378 | 0.030 |
Why?
| | Karyotype | 1 | 2013 | 13 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 954 | 0.030 |
Why?
| | Young Adult | 2 | 2021 | 10463 | 0.030 |
Why?
| | Heterografts | 1 | 2013 | 117 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 232 | 0.030 |
Why?
| | Chondrogenesis | 1 | 2013 | 79 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2013 | 267 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2013 | 180 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 635 | 0.020 |
Why?
| | Infant | 2 | 2018 | 7935 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 795 | 0.020 |
Why?
| | Genetic Variation | 1 | 2013 | 876 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 1843 | 0.020 |
Why?
| | Leukocyte Elastase | 1 | 2008 | 79 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 380 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 689 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6124 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 2725 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1699 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2196 | 0.020 |
Why?
| | Brain | 1 | 2012 | 2374 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 17808 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 5035 | 0.010 |
Why?
| | Mice | 1 | 2013 | 14916 | 0.010 |
Why?
| | Animals | 1 | 2013 | 31762 | 0.010 |
Why?
| | Child | 1 | 2008 | 18352 | 0.010 |
Why?
|
|
Schowinsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|